Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bellmunt

Showing results (71-80 of 122) with videos related to

Pageof 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 26, 2000
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancerJ Bellmunt, V Guillem, L Paz-Ares, et al.
The Journal of Pathology|July 19, 2008
Discovery of myopodin methylation in bladder cancerV Cebrian, M Alvarez, A Aleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensityA Ribas, J Albanell, J Bellmunt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancerM Pera, R Gallego, C Montagut, et al.
Actas Urologicas Espanolas|July 16, 2011
[EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]A Heidenreich, J Bellmunt, M Bolla, et al.
Actas Urologicas Espanolas|July 16, 2011
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]N Mottet, J Bellmunt, M Bolla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancerJ Carles, E Esteban, M Climent, et al.
Anticancer Research|March 1, 1996
Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosisJ Albanell, J Bellmunt, R Molina, et al.
Free Radical Biology & Medicine|October 9, 1999
Thyroid status modulates glycoxidative and lipoxidative modification of tissue proteinsR Pamplona, M Portero-Otín, C Ruiz, et al.
Investigational New Drugs|May 23, 2012
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancerC Gómez-Martín, R Salazar, C Montagut, et al.
Pageof 13

Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|July 26, 2000
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancerJ Bellmunt, V Guillem, L Paz-Ares, et al.
The Journal of Pathology|July 19, 2008
Discovery of myopodin methylation in bladder cancerV Cebrian, M Alvarez, A Aleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensityA Ribas, J Albanell, J Bellmunt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancerM Pera, R Gallego, C Montagut, et al.
Actas Urologicas Espanolas|July 16, 2011
[EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]A Heidenreich, J Bellmunt, M Bolla, et al.
Actas Urologicas Espanolas|July 16, 2011
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]N Mottet, J Bellmunt, M Bolla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancerJ Carles, E Esteban, M Climent, et al.
Anticancer Research|March 1, 1996
Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosisJ Albanell, J Bellmunt, R Molina, et al.
Free Radical Biology & Medicine|October 9, 1999
Thyroid status modulates glycoxidative and lipoxidative modification of tissue proteinsR Pamplona, M Portero-Otín, C Ruiz, et al.
Investigational New Drugs|May 23, 2012
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancerC Gómez-Martín, R Salazar, C Montagut, et al.
Pageof 13